BlackRock’s Fibrocell Science Inc. FCSC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-8,318
Closed -$25K 5136
2019
Q3
$25K Hold
8,318
﹤0.01% 4624
2019
Q2
$16K Hold
8,318
﹤0.01% 4717
2019
Q1
$16K Hold
8,318
﹤0.01% 4633
2018
Q4
$13K Buy
8,318
+2
+0% +$4 ﹤0.01% 4638
2018
Q3
$19K Buy
8,316
+1
+0% +$2 ﹤0.01% 4664
2018
Q2
$23K Sell
8,315
-1
-0% -$3 ﹤0.01% 4662
2018
Q1
$25K Sell
8,316
-215
-3% -$705 ﹤0.01% 4540
2017
Q4
$28K Hold
8,531
﹤0.01% 4515
2017
Q3
$130K Hold
8,531
﹤0.01% 4322
2017
Q2
$171K Sell
8,531
-5,438
-39% -$67.1K ﹤0.01% 4293
2017
Q1
$140K Buy
+13,969
New +$155K ﹤0.01% 4279
2016
Q2
Sell
-25
Closed -$1K 3866
2016
Q1
$1K Buy
+25
New +$998 ﹤0.01% 3603

BlackRock's FCSC Position: Q4 2019 in Review

BlackRock sold out of Fibrocell Science Inc. (FCSC) in Q4 2019, closing a stake of 8,318 shares — an estimated $25K sold.

BlackRock first reported a position in FCSC in Q1 2016 and held it in 12 quarters. The position peaked at $171K in Q2 2017. 0 funds tracked by Wall St. Rank hold FCSC as of Q4 2019.

  • BlackRock reported no remaining Fibrocell Science Inc. position as of Q4 2019 after selling out during the quarter.
  • BlackRock sold 8,318 Fibrocell Science Inc. shares in Q4 2019, an estimated $25K.
  • BlackRock first reported a position in Fibrocell Science Inc. in Q1 2016 and held it in 12 quarters.
  • BlackRock's Fibrocell Science Inc. position peaked at $171K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Fibrocell Science Inc. as of Q4 2019.

Based on BlackRock's 13F filing for Q4 2019, filed 13 Feb 2020.